Tejas Savant
Stock Analyst at Morgan Stanley
(2.40)
# 2,425
Out of 5,182 analysts
245
Total ratings
43.75%
Success rate
-0.16%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $48 → $37 | $33.85 | +9.31% | 16 | Mar 6, 2026 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $24 → $19 | $16.18 | +17.43% | 4 | Mar 6, 2026 | |
| PSNL Personalis | Maintains: Equal-Weight | $11 → $10 | $5.96 | +67.79% | 15 | Mar 5, 2026 | |
| TEM Tempus AI | Maintains: Overweight | $85 → $70 | $52.68 | +32.88% | 7 | Mar 3, 2026 | |
| NTRA Natera | Maintains: Overweight | $265 → $250 | $204.39 | +22.32% | 16 | Mar 3, 2026 | |
| GRAL GRAIL | Maintains: Equal-Weight | $110 → $60 | $55.02 | +9.05% | 4 | Feb 24, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $468.04 | +43.15% | 16 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $163.84 | +61.74% | 12 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $22.28 | -10.23% | 16 | Dec 2, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $11 → $16 | $14.21 | +12.60% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $128.52 | -18.30% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $7.97 | +50.56% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $8.61 | -7.08% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $4.46 | +56.95% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $10.38 | -32.56% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.68 | +35.87% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $4.83 | +334.78% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.59 | +25.79% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $7.82 | +411.51% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.57 | +133.46% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.86 | +105.76% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $2.36 | +16.53% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.95 | +412.82% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $88.50 | -17.51% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $171.23 | +46.00% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $10.13 | +887.65% | 5 | May 12, 2022 |
Veracyte
Mar 6, 2026
Maintains: Underweight
Price Target: $48 → $37
Current: $33.85
Upside: +9.31%
Stevanato Group
Mar 6, 2026
Maintains: Equal-Weight
Price Target: $24 → $19
Current: $16.18
Upside: +17.43%
Personalis
Mar 5, 2026
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $5.96
Upside: +67.79%
Tempus AI
Mar 3, 2026
Maintains: Overweight
Price Target: $85 → $70
Current: $52.68
Upside: +32.88%
Natera
Mar 3, 2026
Maintains: Overweight
Price Target: $265 → $250
Current: $204.39
Upside: +22.32%
GRAIL
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $110 → $60
Current: $55.02
Upside: +9.05%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $468.04
Upside: +43.15%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $163.84
Upside: +61.74%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $22.28
Upside: -10.23%
Adaptive Biotechnologies
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $14.21
Upside: +12.60%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $128.52
Upside: -18.30%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $7.97
Upside: +50.56%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $8.61
Upside: -7.08%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $4.46
Upside: +56.95%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $10.38
Upside: -32.56%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.68
Upside: +35.87%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $4.83
Upside: +334.78%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.59
Upside: +25.79%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $7.82
Upside: +411.51%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.57
Upside: +133.46%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.86
Upside: +105.76%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $2.36
Upside: +16.53%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.95
Upside: +412.82%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $88.50
Upside: -17.51%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $171.23
Upside: +46.00%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $10.13
Upside: +887.65%